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Background. Bacterial ﬂagellin triggers inﬂammation in mammalian cells via Toll-like receptor (TLR) 5. Release of the chemokine
IL-8 in response to ﬂagellin involves NF-κB, p38 MAP kinase, and phosphatidylinositol 3-kinase (PI3K). However, PI3K has been
reported to be either pro- or anti-inﬂammatory in diﬀerent model systems. We hypothesized that this could be due to diﬀerent
activities of the p110α and β isoforms of PI3K. Results. PI3K and Akt were rapidly activated in Caco-2 colon carcinoma cells by
ﬂagellin.Usingaplasmid-basedshRNAdeliverysystemandnovelp110isoform-speciﬁcinhibitors,wefoundthatﬂagellin-induced
IL-8 production was dependent on both p110α and p110β. However in the mouse, inhibition of p110β but not p110α reduced the
increase of serum IL-6 levels induced by intraperitoneal injection of ﬂagellin. Conclusions. These data demonstrate that the p110α
and β isoforms of class IA PI3K are both required for the proinﬂammatory response to ﬂagellin.
1.Background
Flagellin is the major structural protein of bacterial ﬂagella,
the organelles that confer motility to a wide variety of
bacterial species. Flagellin is also a potent trigger of innate
immune responses in eukaryotic cells from plants [1]a n d
vertebrates (reviewed in [2]). Most if not all of the responses
to ﬂagellin in vertebrate epithelial cells are mediated by Toll-
like receptor (TLR) 5 [3–7]. In general, activation of TLRs
by microbial products can lead to the induction of inﬂam-
matory responses via a MyD88-dependent or—independent
pathways, leading to I-κB degradation and ultimately NF-
κB and/or IRF-3 activation [8]. However, divergence and
modulation of TLR signalling with the receptor/ligand pair
is an important component of the innate immune response.
This divergence implicates the involvement of signalling
components other than NF-κB. We and others previously
reported that ﬂagellin-induced production of the neutrophil
chemokine interleukin (IL)-8 requires the activity of p38
MAP kinase, and that inhibition of NF-κB with the I-
κB degradation inhibitor Bay11-7082 results in only slight
inhibition of this TLR5-mediated response [9–11]. Thus,
IL-8 production in response to ﬂagellin challenge depends
signiﬁcantly on NF-κB-independent pathways.
Phosphatidylinositol 3-kinase (PI3K) has been impli-
cated in NF-κB-dependent and –independent inﬂammatory
signaling following TLR ligation. Class IA PI3K consists of
a p85 regulatory subunit and one of several p110 catalytic
subunits (α, β,o rδ), whose primary activity is the addition
of a phosphate to the 3’ position of the phosphatidylinositol-
4,5-diphosphate ring. The class IB PI3K, comprised of
p101 regulatory and p110γ catalytic subunits, has a similar
activity. The resulting product of both enzymes, PI-3,4,5-
P3, activates downstream signaling through several kinases,
most notably Akt and 3-phosphoinositide-dependent kinase
(PDK) 1, leading to cellular responses that vary with the cell2 Mediators of Inﬂammation
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signaling was shown in two previous studies. The ﬁrst of
these, by Yu et al. [9], found that inhibition of PI3K with
the broadly-reactive PI3K inhibitors wortmannin (WM) or
LY294002 (LY29) increased IL-6 and IL-8 production in
response to ﬂagellin in T84 cells, suggesting that PI3K is
inhibitory in the ﬂagellin-mediated signaling of intestinal
epithelial cells (IECs). Moreover, they found that systemic
cytokine release from PI3K p85α−/− mice in response to
intraperitoneal injections of ﬂagellin was signiﬁcantly higher
than in heterozygous littermates. WM increased MAPK
activation but not I-κB degradation in response to ﬂagellin.
The second publication, by Rhee et al. [13], demonstrated
Akt activation in murine colon and nontransformed human
colonic cells (NCM460) treated with ﬂagellin. In contrast to
Yu et al, they found that inhibition of PI3K using dominant-
negative p85 or Akt, or LY29, reduced IL-8 production in
responsetoﬂagellin,indicatingthatPI3Kaugmentsﬂagellin-
mediated inﬂammatory responses in IECs.
To help reconcile these discrepant results, we ﬁrst
conﬁrmed that ﬂagellin stimulates PI3K enzymatic activity
in Caco-2 cells, and then assessed the impact of PI3K
inhibition on ﬂagellin-mediated inﬂammatory signaling by
directly inhibiting the two class 1A PI3K isoforms expressed
inIECs,p110α,andp110β [14],usingbothRNAinterference
and novel, isoform-speciﬁc pharmacological inhibitors. We
found that inhibition of p110α or β signiﬁcantly decreased
ﬂagellin-induced IL-8 release, although inhibition of these
isoforms produced distinct eﬀects on MAPK activation and
IL-8 mRNA concentrations in human IECs as well as in an
in vivo mouse model of ﬂagellin inﬂammatory responses.
The ﬁndings suggest that the PI3K pathway has a net
proinﬂammatory eﬀect in TLR5 signaling, and that the
discrepant results reported in the literature could be due to
diﬀerences in p110 isoform activities.
2. Methods
2.1. Reagents. Culture media and supplements were pur-
chased from Sigma (St. Louis) except where otherwise
indicated. Antibodies included mouse anti-PK (Serotec;
Oxford, UK); mouse anti-PI3K p85, rabbit anti-pSer473Akt,
and mouse 4G10 antiphosphotyrosine (Upstate; Char-
lottesville, VA); rabbit antiphospho-p38 T180/Y182, total p38,
phospho-p44/42 T202/Y204, total p44/42 (Cell Signaling;
Beverly, MA); mouse anti-GAPDH (RDI; Flanders, NJ);
rabbit anti-I-κBα C-15 and goat anti-actin (Santa Cruz
Biotechnology; Santa Cruz, CA); HRP goat anti-mouse
(Cedar Lane; Hornby, ON); HRP mouse anti-rabbit IgG
(Sigma). LY294002, Bay 11-7085, and LY303511 were pur-
chased from Calbiochem (San Diego). Isoform-speciﬁc PI3K
inhibitors for in vitro studies were provided by Kevan
Shokat (University of California, San Francisco) [7, 15].
TGX-221 and PI-103 used in mouse experiments were
purchased from Chemdea (Ridgewood, NJ) Recombinant
LPS-free E. coli H18 ﬂagellin was produced as previously
d e s c r i b e di n[ 16]. The human IL-8 and mouse IL-6 ELISAs
were from R&D Systems (Minneapolis, MN). Flagellin
was used at saturating concentrations (500–1000μg/ml)
for proximal signaling events in Caco-2 cells, and at
100ng/ml in experiments involving PI3K inhibitors or
shRNA as this dose is the threshold dose for maximal IL-8
production.
2.2. Cell Culture. Caco-2 cells were obtained from the
American Type Culture Collection (ATCC, Rockville, MD)
andgrowninDMEMwith4.5g/LD-glucose,1xnonessential
amino acids, 2mM glutamine, penicillin (100U/ml), and
streptomycin (100μg/ml) with 10% fetalbovine serum (FBS;
Hyclone,Logan,UT).Caco-2cellswereseededatadensityof
106/ml and used for experiments 5–14 days after becoming
conﬂuent. HEK 293T cells were from ATCC and were
grown in DMEM with 10% heat-inactivated FBS, penicillin,
streptomycin, and nonessential amino acids. T84 cells from
ATCC were grown in DMEM/F12 with 15mM HEPES,
pen/strep, and 5% FBS. They were seeded at 5 ×105 per well
and used 3–4 days after seeding.
2.3. Western Blotting and Immunoprecipitation. Flagellin
treatment of cells cultured in 6- or 12-well plates for
various time points was followed by two washes with ice-
cold phosphate-buﬀered saline (PBS). Treated cells were
then lysed in 250–500μlo fl y s i sb u ﬀer (20mM Tris pH
7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% NP-40,
2.5mM sodium pyrophosphate, 1mM β-glycerophosphate,
1mM N a 3VO4,1 μg/ml leupeptin, and 1mM PMSF) and
equal volumes of protein lysate from each sample analyzed
by Western blotting. For immunoprecipitation of PI3K, 5μg
of anti-p85 was added to 500μg of cell lysate and incubated
at 4◦C overnight. Immune complexes were bound to protein
A-agarose for 1 hour, washed in lysis buﬀer, and analyzed by
Western blot using 4G10 at 1:1000.
2.4.IL-8Promoter/ReporterAssays. Caco-2cellswereelectro-
porated with pEGFP and IL-8 promoter-luciferase reporter
plasmids and seeded in 96-well plates as described in [16].
After 6 days, cells were stimulated and lysed in Bright-Glo
reagent (Promega, Madison, WI). The ratio of luminescence
to ﬂuorescence in arbitrary units (to correct for cell number
and transfection eﬃciency) was calculated for each sample,
and the fold increase in this value compared to controls
within the same experiment was deﬁned as the fold increase
in expression.
2.5. In Vitro Kinase Assay for PI3K. C a c o - 2c e l l sw e r eg r o w n
at least 5 days postconﬂuence in 6-well plates. They were
serum starved overnight, and then treated with ﬂagellin for
brief time points (1–30 minutes). Cells were rinsed with
cold PBS, lysed, and immunoprecipitated with anti-p85 and
protein A agarose. During the second wash step, 20% of the
total volume of beads from each tube was removed and ana-
lyzed by Western blot for total amount of p85 (IP control).
Remaining immunoprecipitates were subjected to in vitro
kinaseassayasdescribedin[17].Kinaseautoradiographsand
p85 Western blots were scanned and analyzed by densito-
metry, and the ratio of these two values calculated for each
sample.Mediators of Inﬂammation 3
2.6. Electrophoretic Mobility Shift Assay for NF-κB. Caco-2
cells seeded in 6-well plates were used at least 7 days after
plating. Cells were fed with 1ml fresh growth medium and
incubated with signaling inhibitors for 60 minutes followed
byﬂagellinor IL-1β for30–60minutes.Nuclearextractswere
incubated with 32P-labeled NF-κB-binding oligonucleotide
and analyzed by EMSA as described in [18].
2.7. Quantitative RT-PCR. Caco-2 cells grown to diﬀerenti-
ation in 24-well plates were pretreated with pharmacologic
inhibitorsfor30minutesandthenstimulatedfor60minutes.
Cells were lysed and cytoplasmic RNA isolated (Rneasy mini,
Qiagen;Mississauga,ON).EqualamountsofRNAfromeach
samplewerereverselytranscribedusingSuperscriptII(Invit-
rogen), and equal volumes from each reaction subjected to
real-time PCR using Sybr Green (Applied Biosystems; Foster
City, CA) for ﬂuorescent detection. Fold changes in IL-8
mRNA were standardized to GAPDH standards for each
sample and calculated as described in [18].
2.8.ConstructionandAnalysisofshRNAMediatedKnockdown
of p110 Subunits. Target sequences for shRNA-mediated
knockdowns of p110α and p110β were as follows: PIK3CA
(Acc. NM 006218), 224-244, and PIK3B (Acc. NM 006219)
1140-1161. Knockdown vectors were constructed by cloning
the following oligonucleotides into the BglII and HindIII
sites of pSUPER (OligoEngine): p110-α1-ATGTTTACTA-
CCAAATGGA (226-244); p110-α2-GGTGGAATGAATG-
GCTGAA (1302-1320); p110-β1- TGGAATGAACCACTG-
GAAT (1141-1159); p110-β2-CTGTCACTTGTGGGATTGT
(481-499). HEK-293T cells were seeded at 105/well in
24-well plates and transfected 16–24 hours later with 50ng
of TLR5 and 500ng of pSuper or derived knockdown vector
plus 1.25μl of Lipofectamine 2000 (Invitrogen) per well,
according to the manufacturer’s instructions. After an
additional 24 hours the medium was changed, and cells
were stimulated with 500ng/ml of ﬂagellin 48 hours after
transfection. Supernatant was harvested for IL-8 deter-
mination after 6 hours, and mRNA was quantiﬁed by
QPCR as described above using the following oligo-
nucleotides: p110α5 -ACGTGTGCCATTTGTTTTGAC and
5 -TTATGAAGAGATTGGCATGCTG; p110β:5  -AAAAA-
ACTGGCCAGCTCT and 5 -TAATGCAAGAGAGTCCTT.
Knockdown ratios were expressed as a fold decrease in
mRNA expression compared to cells expressing empty
pSUPER vector, using the calculation method described
above for Caco-2 cells.
2.9. Mouse Injections. 6-12-week-old female C57Bl/6 mice
bred in our animal care facility were cared for in accordance
with the guidelines of the UBC Animal Care and Use
Committee in accordance with Canadian regulations. Mice
were injected intraperitoneally with inhibitors or DMSO
vehicle as described in Results, followed 30 minutes later
by 10μg of ﬂagellin in 100μl of sterile phosphate-buﬀered
saline(PBS).Bloodwastakenviathesaphenousveinpriorto
injectionand90minutesand3hoursafterﬂagellininjection.
At 6.5–7 hours after injection, mice were euthanized by CO2
asphyxiation and blood taken by cardiac puncture. Sera were
stored at −80
◦C until testing for IL-6 by ELISA.
2.10. Statistical Analysis. Statistics were performed on orig-
inal data using the VassarStats statistical computation
website (http://vassun.vassar.edu/∼lowry/VassarStats.htm).
Except where noted, multiple groups were analyzed by
ANOVA to verify the presence of signiﬁcant diﬀerences; this
was followed by testing of individual pairs by t-test or Tukey
HSD.
3. Results
3.1. Flagellin Causes Enzymatic PI3K Activation in Caco-
2C e l l s .Activity of PI3K in cell lysates was measured by
in vitro kinase assay. As shown in Figure 1(a),C a c o - 2
cells possessed measurable basal PI3K activity, consistent
with their transformed nature and reduced intrinsic PTEN
activity [19]. Within 5 minutes of stimulation with ﬂagellin,
a rapid and transient increase in PI3K activity was measured.
This activity returned to baseline after 30 minutes (not
shown). As an additional test for PI3K activation, Caco-
2 lysates were immunoprecipitated with anti-PI3K p85
followed by Western blot using antiphosphotyrosine (4G10).
As shown in Figure 1(b), ﬂagellin-treated cells had a time-
dependent increase in signal versus controls, indicating
tyrosine phosphorylation of PI3K, which is associated with
PI3K enzymatic activation [20].
3.2. Flagellin-Induced NF-κB Activity Is Not PI3K Dependent.
We next analyzed I-κBd e g r a d a t i o na n dN F - κB localization
and DNA binding activity in response to ﬂagellin. As shown
inFigure 2(a),ﬂagellin-induceddegradationofI-κBinCaco-
2 cells was not signiﬁcantly aﬀected by LY29, but was
reduced by Bay11-7082. We next examined NF-κBn u c l e a r
localization and DNA binding activity by EMSA. As shown
in Figures 2(b) and 2(c), ﬂagellin caused a large increase in
NF-κB activity in Caco-2 cells that was not reduced by LY29.
3.3. PI3K Inhibition Reduces IL-8 Promoter Activity, mRNA
Production, and Secretion in Caco-2 Cells. Yu et al. [9]
showed that LY29 increased IL-8 production in T84 trans-
formed human colonocytes. This stands in contrast to Rhee
et al. [13], who found that LY29 inhibited ﬂagellin responses
in NCM460 nontransformed human colonocytes. To recon-
cile this discrepancy, we measured IL-8 production in Caco-
2 cells. As shown in Figure 3(a), Caco-2 cells transiently
transfected with an IL-8 promoter/luciferase reporter con-
struct that had approximately a 4-fold increase in luciferase
expression after treatment with ﬂagellin. Pretreatment of
cells with 30μM LY29 reduced ﬂagellin-induced luciferase
expression by about one-fourth (0.76 ± 0.29; P<. 05). LY29
also inhibited IL-1β-induced luciferase expression (0.54 ±
0.023; P<. 001, t-test; not shown).
The eﬀect of PI3K inhibition on IL-8 mRNA production
was measured by quantitative real-time RT-PCR. As shown
in Figure 3(b), ﬂagellin caused a marked increase in IL-8
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Figure 1: Activation of PI3K in Caco-2 cells by E. coli ﬂagellin. (a) In vitro kinase assay. Caco-2 cells treated with ﬂagellin (FliC) 1μg/ml
for the indicated times were lysed and immunoprecipitated with anti-p85. An aliquot of each immunoprecipitate was analyzed by Western
blot for p85, and the remainder was reacted with phosphatidylinositols and γ-32P-ATP and separated by thin-layer chromatography. The
PIP3 band is indicated by the arrow. Densitometry performed on autoradiograms from three independent experiments is shown below.
∗P<. 05, FliC versus control (t-test). (b) Tyrosine phosphorylation of PI3K. Caco-2 cells treated with 500ng/ml ﬂagellin for the indicated
times were lysed and immunoprecipitated with anti-p85. Precipitates were separated by SDS-PAGE and Western blots performed using
4G10 antiphosphotyrosine. Blots were stripped and reprobed with anti-p85 to conﬁrm equal eﬃciency of immunoprecipitation. Results are
representative of two separate experiments.
ﬂagellin-stimulated IL-8mRNA amountsby aboutone-third
compared to DMSO vehicle (P<. 05). As LY29 has been
reported to aﬀect kinases other than PI3K, such as the
mammalian target of rapamycin (mTOR) and casein kinase
2 (CK2), we tested an analogue, LY303511 (LY30), which
lacks PI3K inhibitory activity but does inhibit mTor and
CK2[21–23].Theinactiveanalog,LY30,didnotsigniﬁcantly
reduce IL-8 mRNA expression (not shown). In contrast, two
isoform-speciﬁc PI3K inhibitors (described below) showed
disparate eﬀects, with TGX-221 (p110β) causing an increase
in IL-8 mRNA, and PI-103 (p110α) producing no eﬀect
(Figure 3(b)).
We next measured the eﬀects of PI3K inhibitors on IL-
8 release from ﬂagellin-stimulated Caco-2 cells. For these
e x p e r i m e n t sw eu s e dL Y 2 9a sw e l la san e w l y - a v a i l a b l e ,
broadly-reactive PI3K inhibitor, GDC0941. Pretreatment of
cells with LY29 or GDC0941 signiﬁcantly inhibited ﬂagellin-
induced IL-8 release (Figure 4(a)). We also tested eﬀects
of LY30, rapamycin (the prototype mTOR inhibitor), and
pp242 (a novel mTor inhibitor). None of these inhibitors
signiﬁcantly inhibited ﬂagellin-induced IL-8 release from
Caco-2 cells, suggesting that the eﬀects seen with LY29 and
GDC0941 were in fact due to PI3K inhibition rather than
oﬀ-target eﬀects on mTOR or CK2. (Figure 4(a)). Absolute
values of released IL-8 in the DMSO + ﬂagellin treated cells
ranged from 400–800pg/ml.
3.4. p110α and p110β A r eB o t hR e q u i r e df o rF l a g e l l i n - I n d u c e d
Signaling in Caco-2 Cells. To determine whether ﬂagellin-
induced inﬂammation requires a particular isoform of class
Ia PI3K, we employed a panel of novel chemical agents with
speciﬁcity for diﬀerent p110 catalytic subunits. A list of these
and standard agents is found in Table 1. In addition to LY29,
TGX-221, and PI-103 signiﬁcantly inhibited IL-8 release,
despite their disparate eﬀects on IL-8 mRNA (Figure 4(b)).
Both compounds also inhibited CCL20 release from Caco-2
cells, as did LY29 (see Figure 4(c) in Supplementary Material
available online at doi: 10.1155/2010/652098). In contrast
to Caco-2 cells, T84 cells showed no signiﬁcant change in
ﬂagellin-induced IL-8 production with LY29, TGX-221, or
PI-103, and had a signiﬁcant increase in IL-8 with WM
(4.8 ± 1.4-fold increase; P<. 001, t-test, see Figure 4d inMediators of Inﬂammation 5
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Figure 2: Flagellin-induced I-κBd e g r a d a t i o na n dN F - κB activation in Caco-2 cells are PI3K independent. (a) I-κBα degradation in Caco-2
cells treated with IL-1β (10ng/ml) or ﬂagellin (FliC, 1000ng/ml or 500ng/ml) was not inhibited by LY29 (30μM) but was inhibited by Bay
11-7082 (20μM). Caco-2 cell lysates were analyzed by Western blot for anti-IκBα and anti-GAPDH and the band density measured. Density
of I-κB bands was divided by GAPDH to normalize for protein loading and transfer, and the ratio was taken versus unstimulated cells in
each experiment to calculate the amount of I-κBα degradation. Results were pooled from four separate experiments. P<. 01 versus DMSO
by ANOVA, DMSO + FliC versus Bay11 + FliC. (b) NF-κB activation in Caco-2 cells measured by electrophoretic mobility shift assay, with
the shifted NF-κB band indicated by the arrow. (c) Densitometry measurements of NF-κB-bound probe bands, pooled from 3 independent
experiments.
Supplementary Material). These results support those of
Yu et al. [9], and suggest that PI3K signaling in IECs varies
between cell types.
As the speciﬁcity of pharmacological inhibitors is
imperfect, we sought to conﬁrm these results, using RNA
interference. shRNA constructs were cloned into the pSuper
vector, using sequences reported in the literature to be
eﬀective at knocking down the class IA PI3K catalytic
isoforms p110α and p110β, both of which are known to be
expressedinCaco-2cells.BecauseCaco-2cellshaverelatively
low transfection rates, we looked at IL-8 secretion in HEK
293T cells, which are highly transfectable and produce IL-8
in response to ﬂagellin when transfected to overexpress
TLR5 (they are minimally responsive to ﬂagellin otherwise).
As with Caco-2 cells, LY29 decreased ﬂagellin-mediated
IL-8 release from HEK 293T cells (37.3 ± 4.1% inhibition
with LY29; not shown). Multiple sequences were selected
from each p110 isoform and cloned into pSuper to generate
a panel of shRNA-expressing plasmids. Knockdown of
speciﬁc p110 mRNA was conﬁrmed by QPCR. The diﬀerent
knockdown constructs reduced IL-8 secretion in ﬂagellin-
stimulated, TLR5 transfected HEK cells in proportion
with their degree of knockdown as determined by QPCR
(Figure 5). All constructs shown in Figure 5 signiﬁcantly
reduced IL-8 secretion in comparison to pSuper transfected
cells (P<. 01byANOVAfollowedbyt-test).Asanadditional
control, we found that two knockdown constructs for p110γ
failed to inhibit IL-8 production (not shown). The absolute
concentration of IL-8 produced in TLR5-expressing cells
carrying empty pSuper was 182.3 +/− 96pg/ml (N = 4).6 Mediators of Inﬂammation
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Figure 3:PI3Kinhibitionreducesﬂagellin-stimulatedIL-8promoteractivationandmRNAproduction.(a)Caco-2cellswereelectroporated
with and IL-8 promoter/luciferase reporter plasmid and pEGFP as a transfection marker and grown as described in Methods. Cells were
pretreated with inhibitors at the concentrations shown (or an equivalent volume of DMSO vehicle) followed 30 minutes later by ﬂagellin
100ng/ml. After 6 hours, cells were harvested for luciferase assay and ﬂuorescence determination. The RLU/RFU value was calculated for
each well, and these data normalized to the wells stimulated with DMSO + ﬂagellin in each individual experiment. Data shown are compiled
from at least 3 experiments for each inhibitor. ∗P<. 01 (t-test). (b) IL-8 mRNA measurements by quantitative RT-PCR compiled from at
least 3 experiments. Cytoplasmic RNA isolated from cells treated as shown was reverse transcribed. cDNA was ampliﬁed using actin and IL-8
primers with real-time ﬂuorescent quantitation. Fold increases in mRNA were calculated as described in Methods. Results are expressed as
the ratio compared to cells treated with ﬂagellin plus DMSO vehicle.
∗∗P <. 05 versus ﬂagellin plus DMSO (t-test).
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Figure 4: PI3K inhibition reduces IL-8 production after ﬂagellin stimulation in Caco-2 cells. Caco-2 cells seeded as described in Methods
were treated with the inhibitors shown (all at 10μM, except for 30μM LY29 and LY30) or an equivalent dose of DMSO vehicle in complete
culture media. Thirty minutes later, ﬂagellin was added to a ﬁnal concentration of 100ng/ml, and cell supernatants harvested 3 hours later.
IL-8wasmeasuredbyELISA,andthevaluesineachexperimentwerenormalizedtotheﬂagellin+DMSOwells.(a)Eﬀectsofbroadlyreactive
PI3K inhibitors. (b) Eﬀects of isoform-speciﬁc inhibitors. ∗P<. 001 versus DMSO;
∗∗P <. 01 versus DMSO (t-test). Results compiled from
N of at least 10 for each inhibitor.Mediators of Inﬂammation 7
Table 1: Activities of pharmacologic inhibitors used in this study (IC50 in nM).
Enzyme LY294002 LY303511 GDC0941 PI-103 TGX-221 PIK-93
p110α 500 >1000 3 8 >1000 39
p110β 300–973 >1000 33 88–340 7–8.5 590
p110γ 1000–7000 >1000 75 15 >1000 16
p110δ 570–1300 >1000 3 48->500 >100 120
mTor Active ? 580 20 ? 1380
other CK2 ? Class II PI3K (0.67) PI4KIIIb
Data compiled from [24–28].
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Figure 5: Eﬀect of p110α- and p110β-targeted shRNA on IL-
8 production in TLR5-transfected, ﬂagellin-stimulated HEK293T
cells. Cells were transfected with TLR5 and a pSuper derivative or
with pSuper alone and then stimulated with 500ng/ml ﬂagellin for
6 hours. IL-8 concentrations were determined by ELISA. pSp110-
α1 and -α2 target 2 separate sites of p110α, while pSp110-β1a n d
-β2 target two separate sites of p110β. Results show fold increase
versus baseline (IL-8 amounts measured in ﬂagellin stimulated cells
which were not transfected with TLR5). The percentages above
the columns denote the amount of knockdown of either p110α
or p110β mRNA as determined by quantitative RT-PCR; results
were compiled from at least 7 samples from a minimum of 3
separate experiments. All four knockdowns signiﬁcantly reduced
IL-8 production (P<. 001, ANOVA).
3.5.PI3KInhibitionAltersp38andERKActivationinResponse
to Flagellin. To determine the mechanisms by which PI3K
inhibition reduced ﬂagellin responses, we looked at the
eﬀects of PI3K inhibition on Akt and MAPK activation. It
has been previously reported that ﬂagellin causes phospho-
rylation of Akt, p38, and Erk kinases; moreover, Yu et al
reported that PI3K inhibition led to prolonged activation
of these kinases in T84 cells [9]. Both TGX-221 and PI-103
inhibited ﬂagellin-induced Akt phosphorylation at Ser473,
suggesting that the eﬀects of ﬂagellin on PI3K may be
mediated by both p110β and p110α (Figure 6). Flagellin-
induced Akt phosphorylation was also inhibited by LY29
(not shown). Interestingly, both compounds also caused a
substantial increase in p38 phosphorylation at 1 hour, with
less pronounced upregulation for as long as 4 hours after
stimulation. In contrast, ERK phosphorylation followed an
DTPDT P DT PD T P
0 1 h2 h4 h
pERK
P38
pP38
Akt
Akt
pAkt
Figure 6: Eﬀects of p110 inhibitors on ﬂagellin-induced Akt, p38,
andERKactivation.Caco-2cellswereserum-starvedovernight,and
thengivenserum-containingmediawith10μMPI-103(P)orT GX-
221 (T) or an equivalent volume of DMSO vehicle (D). After 30
minutes, ﬂagellin was added to a ﬁnal concentration of 100ng/ml,
and cells were harvested after 1, 2, or 4 hours. Total cell lysates were
separated by SDS-PAGE and tested for pSer473-Akt, phospho-p38,
and phospho-ERK by Western blot. Blots were stripped and probed
with total Akt and total p38 antibodies as loading controls. Results
shown are typical of three independent experiments.
unexpected kinetic course, with both inhibitors reducing
immediate and 2 hours phosphorylation, while TGX221, but
notPI-103,causedasigniﬁcantboostinlatephosphorylation
(4 hours after stimulation). Together, these results point to a
complex interaction between the PI3K and MAPK pathways
following TLR5 activation, and reveal diﬀerent activities of
p110α and p110β in the late regulatory pathways.
3.6.PI3Kp110β Inhibition Reduces Inﬂammatory Responses to
F l a g e l l i nI nV i v o .To measure the in vivo relevance of PI3K
isoform activation, we examined the serum IL-6 response
to intraperitoneal injection of ﬂagellin into mice. IL-6 is
commonly used as a serum marker for ﬂagellin-induced
inﬂammatory responses in mice, which do not produce IL-
8. Yu et al performed similar experiments comparing wild-
type to p85α−/− mice and found exaggerated responses in
the absence of functioning PI3K [9]. Female C57Bl/6 mice
were injected with 100–300μl of TGX-221 or PI-103 in
DMSO, or an equivalent volume of DMSO alone, followed
30 minutes later by 10μg of ﬂagellin in PBS. Blood was
taken at 90 minutes, 3 hours, and 7 hours following the
ﬂagellininjection, andserumIL-6measured.Somemicealso
had preinjection blood taken, to establish a baseline, which8 Mediators of Inﬂammation
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Figure 7: Eﬀects of p110 inhibitors on murine responses to
ﬂagellin in vivo. Female C57Bl/6 mice (6–12 weeks) were injected
intraperitoneally with 200μg of TGX-221 or PI-103 in 75% DMSO
in PBS, or an equivalent volume of DMSO/PBS. Thirty min later,
mice were injected intraperitoneally with 10μgo fE. coli H18
ﬂagellin in 100μl of PBS. Saphenous blood was taken after an
addition 90 minutes and 3 hours. Sera were analyzed for IL-6
concentration byELISAand resultsexpressed as theratiocompared
to ﬂagellin plus DMSO control at each time point. Mean serum
concentrations of IL-6 in the ﬂagellin plus DMSO vehicle group
were 1567pg/ml at 90 minutes and 4915pg/ml at 3 hours. N = 4
per group. ∗P<. 05, TGX-221 versus DMSO, t-test.
in all cases was less than or equal to 125pg/ml. All mice
exhibited mildly reduced physical activity following these
injections, which may be due to the known depressant eﬀects
of DMSO. No mice died or exhibited any other signs of
distress such as stereotypic movements, hunched posture,
ruﬄedfur,etc.AsshowninFigure 7,mic etr eat edwithT GX-
221 had a statistically signiﬁcant reduction in serum IL-6 90
minutes after ﬂagellin injection, compared to DMSO vehicle.
Serum from PI-103-treated mice contained increased IL-6,
although this was not statistically signiﬁcant. At 3 hours,
the diﬀerences were no longer evident. It should be noted
that the serum half-life of PI-103 in mice is reportedly
short, although tissue clearance is much slower [29]. The
serum half-like of TGX-221 has not been reported, but
antithrombotic activity in rats persists for at least 60–90
minutes following an intravenous bolus [16].
To verify the purity of our ﬂagellin preparations, C57Bl/6
TLR5 −/− mice were injected with the same dose and
preparation of ﬂagellin and IL-6 measured. Three-hour IL-
6 production was minimal in these mice compared to wild-
type mice (345 ± 27.2 versus 7655 ± 378.5pg/ml,P<. 001,
not shown). Serum IL-6 was below assay detection limits
(50pg/ml) in mice prior to ﬂagellin treatment.
4. Discussion
Our results indicate that PI3K activated upon TLR5 acti-
vation by ﬂagellin has a net proinﬂammatory eﬀect in
Caco-2 cells, and that this eﬀect is not mediated through
upregulation of NF-κBo rp 3 8M A P Ka c t i v i t y .M o r e o v e r ,
we have shown that both the p110α and p110β isoforms
contribute to this eﬀect, although likely through diﬀerent
mechanisms involving ERK phosphorylation and possibly
IL-8 mRNA translation, which may lead to nonredundant
eﬀects in vivo.
These ﬁndings are particularly relevant because of the
current controversy surrounding the role of PI3K in TLR
signaling, with both pro- and anti-inﬂammatory eﬀects
seen in various epithelial and hematopoietic cells from
mice and humans. Moreover, diﬀerences in TLR5 activity
have been implicated in several human diseases, including
Crohn’s disease [30], systemic lupus erythematosus [31],
and Legionella pneumonia [32]. While TLR5 is expressed
on both epithelial and hematopoietic cells, these cells diﬀer
tremendously in their exposure to the natural TLR5 ligand,
ﬂagellin.Hence,it is not surprising thatsignaling in response
to ﬂagellin would diﬀer between these cell types, and the
involvement of downstream kinase messengers such as PI3K
is one way that this diﬀerence can be achieved.
Class IA PI3K is a proximal transducer of a wide
variety of extracellular signals. Stimuli such as growth
factors, G-protein coupled receptor ligands, cytokines, and
vitamin D3 can recruit the p85 regulatory subunit to
the plasma membrane, where the p110 catalytic subunit
converts (preferentially) PI-4,5-P2 into PI-3,4,5-P3 [10]. PI-
3,4,5-P3 binds to and regulates several protein kinases and
other targets through their pleckstrin-homology domains.
The most studied of these targets are phosphatidylinositol-
dependent kinase 1 (PDK1), Akt (protein kinase B), tyrosine
kinases, and guanosine nucleotide exchange factors [12].
Further downstream, other proteins such as I-κB kinase
subtypes (IKK), mTOR, protein kinase C-ξ, and several
antiapoptotic factors can then be activated, making PI3K
an important proximal element in many signal transduction
pathways [33].
There are two distinct p85 isoforms (α and β)a n df o u r
p110 isoforms (α, β, γ,a n dδ). The tissue distributions of
these are distinct, with all four p110 isoforms expressed on
hemopoietic cells but only α, β,a n dγ expressed in normal
epithelial cells. Of note, p110γ expression is absent in colonic
adenocarcinoma cells, including Caco-2 cells [15]. While
all of the subunits appear to catalyze the same enzymatic
reactions, there are diﬀerent cellular responses associated
with them, some of which may be due to unique localization,
or even nonenzymatic activities. For example, p110β was
shown to bind to Akt in the nucleus of 3T3 cells, facilitating
DNA elongation during replication [34]. In contrast, p110α
was required for cell survival in the same study.Mediators of Inﬂammation 9
In TLR and IL-1β signaling, PI3K is believed to be
recruited to the membrane by binding of p85 to a speciﬁc
YXXM motif on MyD88, leading to activation of PI3K
[13]. However, in the case of TLR4, binding of PI3K may
result in phosphoinositide sequestration and subsequent
reduced activity of the PI3K axis [35]. Overall, the net eﬀect
of PI3K activity can be either pro- or anti-inﬂammatory
depending on the system studied. For example, inhibition
of PI3K increases COX-2 upregulation in response to TNF-α
or IL-1 in colonic epithelial cells [36] but decreases COX-
2 upregulation by lauric acid in RAW macrophages [37].
InhibitionofPI3KwithLY29orWMreducesIL-8expression
in some experimental models, but not others [38–41]. Even
within the same cell type, PI3K can diﬀerentially aﬀect
inﬂammatory gene expression. For example, LY29 reduces
expression of MIP-1α and MIP-1β mRNA, but increases IL-8
mRNA in dendritic cells incubated with LPS [42]. Eﬀects of
PI3K on NF-κB also vary with the system studied, and can
involve either inhibition or activation of NF-κBi na nI - κB-
dependent or –independent manner [43–47].
OneproblemwithmanypublishedstudiesofPI3Keﬀects
is that the use of pharmacologic inhibitors is inconsistent,
with wortmannin (WM), LY29, or both used in diﬀerent
reports. While WM at concentrations below 50nM is quite
speciﬁcforPI3K,itdoeshaveactivityagainstsmooth-muscle
myosinlight-chainkinase(IC50 of260nM)[23].Whilemore
stable than WM, LY29 is less potent, and inhibits CK2 and
mTOR at similar concentrations at which it inhibits PI3K
[21, 23]. These activities could explain diﬀerent or even
opposite pharmacologic eﬀe c t so fL Y 2 9a n dW Mr e p o r t e di n
various cell systems [48–50].
Because of these issues, several more recent studies
have focused on the roles of speciﬁc p110 isoforms in
TLR signaling. While there are no reports examining p110
isoforms in TLR5 signaling, they have been studied in
TLR4 pathways. Utsugi et al. found that p110β,b u tn o t
α, positively regulated LPS-induced IL-12 production in
human DCs and macrophages [51]. In contrast, in murine
macrophages, Tsukamoto et al. found that shRNA-mediated
inhibition of p110α increased Akt phosphorylation and
decreased iNOS activity and IL-12 production, while p110β
inhibition had the opposite eﬀect on these markers [52].
They concluded that p110β is involved in downregulation or
negative feedback of TLR signaling. While these results are
consistent with the late increase in pERK that we observed
following ﬂagellin stimulation in the presence of TGX-
221, in other ways our ﬁndings were quite diﬀerent. For
example, we found that TGX-221 and PI-103 were equally
eﬀective at reducing ﬂagellin-induced Akt phosphorylation,
and that TGX-221, but not PI-103, reduced IL-6 production
in response to ﬂagellin injection in mice.
The isoform-speciﬁc pharmacologic inhibitors of PI3K
used in this study are starting to prove very useful in deter-
mining the roles of individual p110 isoforms, particularly in
models where shRNA is impractical (such as primary cells
or in vivo). For example, Sly et al. found that inhibition of
p110β withTGX-221increasedTLR4-orTLR9-mediatedIL-
6 production in murine macrophages whereas p110α, γ,a n d
δ inhibitors had the opposite eﬀect [53]. The highly speciﬁc
nature of these inhibitors has generated interest in their use
in diverse clinical settings, including platelet inhibition and
cancer treatment. However, the eﬀects of these agents on
TLR5signaling,orindeedonIECsinanymodelsystem,have
not been examined previously.
The relevance of our ﬁndings is further increased by
the existing controversy regarding the role of PI3K in TLR
signalingingeneral,andparticularlyonTLR5.Asmentioned
above, Yu et al. and Rhee et al. found opposite eﬀects of
PI3KinhibitiononTLR5signaling(anti-inﬂammatoryinthe
former and proinﬂammatory in the latter). An additional
paper by Kato et al. reported inhibition of TLR5 signaling
by WM in TLR5-transfected HEK cells, although this was
not the major focus of their work [54]. We hypothesized that
diﬀerential eﬀects of p110α and β isoforms (which are the
forms expressed in transformed IECs) would be a possible
explanation for these discrepancies.
Our ﬁndings clearly tip the balance in favor or PI3K
having a net proinﬂammatory activity on Caco-2 and HEK
cells, in contrast to RAW cells and T84 cells. We found
that inhibition of either p110α or p110β using shRNA or
pharmacologic blockade led to reduced IL-8 production that
was independent of the NF-κB and p38 pathways. This was
despite either no eﬀect or an activating eﬀect on IL-8 mRNA
detected by RT-PCR. In fact, we found, as did Yu et al,
that PI3K inhibition led to increased p38 phosphorylation
in Caco-2 cells, and a strong proinﬂammatory eﬀect of WM
(but not LY) in T84 cells. Given that blockade of p38 and
NF-κB have both been shown to reduce ﬂagellin-induced
IL-8 production, this ﬁnding was somewhat surprising, and
suggests that an alternative, PI3K-dependent pathway is
involved in TLR5-induced IL-8 production in IECs (perhaps
one involving posttranscriptional regulation). Future studies
will be required to investigate proteins that may be involved
in this pathway.
An additional unexpected observation was the late
increase in ERK phosphorylation after blockade of p110β,
but not p110α. This ﬁnding, along with our in vivo results
in mice, conﬁrm that there are in fact diﬀerent proinﬂam-
matory pathways utilized by p110α and p110β. To the best
of our knowledge, this is the ﬁrst report of the use of TGX-
221 in a live animal model, and its lack of overt toxicity
suggests that it could be useful in further studies whereas
speciﬁc inhibition of p110β may be useful. One interesting
observation was that the inhibition of IL-6 production was
evidentonlyattheearliesttimepoint afterstimulation. Since
the serum half-life of TGX-221 is not known, this could be
strictly due to pharmacokinetic eﬀects, but it is intriguing to
speculate that the late increase of pERK seen in vitro would
reﬂect a biphasic eﬀect of p110β signaling.
In conclusion, it is apparent from our studies that the
TLR5inﬂammatorypathwayinvolvesactivationofPI3K,and
thatinhibitionofeitherp110αorp110βblocksproductionof
IL-8 in Caco-2 IECs in vitro whereas only p110β appears to
berequiredforIL-6productionfrommiceinvivo.M o r eo v e r ,
p110 inhibition reduced IL-8 production while increasing
MAPK activity without altering NF-κB activity, suggesting
the presence of other important molecular targets of PI3K
that ultimately facilitate chemokine production in response10 Mediators of Inﬂammation
to ﬂagellin. Future studies of these novel targets may lead to
the development of novel treatments for ﬂagellin-related dis-
eases, including Crohn’s disease and bacterial gastroenteritis.
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